ARS Pharmaceuticals, Inc.
- SPRY
- NASDAQ
- Biotechnology
- Intranasal Epinephrine (ARS-1)
- Allergy Treatment
$4.02
Today −1.23%Quote Oct 16, 2026, 08:00 PM UTC
−3.13%over the last month
Max drawdown −13.8%From 1-month high −11.8%3 months −37.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$399.8M
Quote Oct 16
Next earnings
Nov 9
Expected, not confirmed
Analyst target
$15.00
+273.1% from here
Floor
$3.99
0.9% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about SPRYPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
195